Document:

EX-10.20(i)

 Exhibit 10.20(i) 

SPONSORED RESEARCH AGREEMENT 

This agreement (the “Agreement”) is made effective 1 April 2014 (the “Effective Date”). 

BETWEEN: 
 THE GOVERNING COUNCIL OF THE
UNIVERSITY OF TORONTO 
 (the “University”)  

-and- 
 PROTAGENIC THERAPEUTICS
CANADA (2006), INC, 
 PROTAGENIC THERAPEUTICS INC. 

(the “Sponsor”)  

(Individually a “Party” and collectively the “Parties”) 

WHEREAS the parties have entered into a Technology License Agreement effective July 21, 2005, as amended, (collectively, the “License
Agreement”) 
 AND WHEREAS the Parties under said License Agreement wish to undertake a research project entitled “Teneurin C-terminal
Associated Peptide (TCAP)-mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism.” as described in the attached Appendix “A” and add this as an
additional Research Agreement under Schedule B of the License Agreement (the “Project”); 
 AND WHEREAS the Sponsor wishes to
support the Project; 
 NOW THEREFORE the Parties hereby agree as follows: 
  

	1.0	THE PROJECT 

  

	 	1.1	Project. The University will perform the Project as described in the attached Appendix “A” which University has determined is in accordance with University policies and procedures. The Project is
consistent with the University’s primary mission, which is education and advancement of knowledge. The manner of performance of the Project shall be determined solely by the Principal Investigator, after consultation with the Sponsor and
subject to substantial compliance in all respects with Appendix “A” and all other provisions of this Agreement, as may be amended from time to time and applicable laws and regulations, including without limitation those governing
the use of animals in research. University will cause diligent efforts to be used to perform the Project in a timely manner and in accordance with appropriate scientific standards. Neither Party makes any warranties or representations regarding its
ability to achieve, nor shall it be bound to accomplish, any particular research objective or results. 

  
 The Governing Council of the
University of Toronto 
 Protagenic Therapeutics, Inc. 

  
 Page 1 

	 	1.2	Principal Investigator. The Project will be performed under the supervision and direction of Prof. David Lovejoy of the Department of Cell and Systems Biology (the “Principal Investigator”), together
with such additional personnel as the Parties may assign. If Dr. Lovejoy becomes unavailable at any time during the Project, the University may nominate a replacement individual as Principal Investigator, such nomination to be made within
fourteen (14) days of the date on which Dr. Lovejoy becomes unavailable. If the Sponsor, for any reason, does not accept the nominated replacement Principal Investigator or a replacement Principal Investigator is not nominated by the
University, as Sponsor’s sole discretion, the Research Program may be amended to reflect a reduced scope of work for the Project, or the Agreement may be terminated by the Sponsor as set forth in Article 5.2. 

 

	 	1.3	Budget. In consideration of the University carrying out the Project, the Sponsor will pay the University the sum of CA$ 75,475 (currency: Canadian Dollars) in compensation for the direct and indirect costs of the
Project, all generally in accordance with the budget contained in the attached Appendix “B”. 

  

	 	1.4	Payment. Subject to Article 5.2, the University shall issue invoices and the Sponsor shall pay the sum set out in Article 1.3 to the University in accordance with the payment schedule in the attached
Appendix “B”. 

  

	 	1.5	Equipment. The University will own any equipment or material purchased by the University under the Project. 

  

	 	1.6	Report. The University will share all data, results research work conclusions and recommendations arising from the performance of the Project (“Research Results”) with Sponsor. The University will
provide reports of Research Results to Sponsor at least on a calendar quarter basis, or as may be reasonably requested by Sponsor, and will include in such reports a meaningful summary of the research accomplished in comparison to the Project
description. The University, through the Principal investigator, will participate in discussions and/or meetings with Sponsor with respect to Research Results and the progress of the Project as may be reasonably requested by the Sponsor. The
University will submit a final report describing the results of the Project to the Sponsor within sixty (60) days of completion of the Project. 

  

	 	1.7	Undertakings. 

  

	 	a.	The University will ensure that, prior to commencement of the Project the Principal Investigator and any replacement shall execute the Principal Investigator’s Undertaking (“PIU”) attached as Appendix
C; any additional personnel, including without limitation, each additional investigator involved in the Project shall execute a Confidential Information and Intellectual Property Agreement (“CIIP”) attached as Appendix D.

  

	 	b.	The University and Principal Investigator shall ensure that all work performed by such personnel on the Project is in compliance with the terms of this Agreement. 

 

	 	c.	In order for University to fulfil its obligations under this Agreement, including without limitation under Section 2.0 of this Agreement, University shall ensure Investigator and additional personnel (including any
and all inventors), as applicable, are obligated to assign and do irrevocably assign any and all of their rights in the Foreground Intellectual Property to the University, including the right to make any claims of priority therefrom

  
 The Governing Council of the
University of Toronto 
 Protagenic Therapeutics, Inc. 

  
 Page 2 

	2.0	INTELLECTUAL PROPERTY 

  

	 	2.1	Definitions. In this Agreement, 

  

	 	a.	“Background Intellectual Property” means Intellectual Property of a Party that is: 

  

	 	i.	proprietary to that Party and was conceived, created, or developed prior to, or independent of, any research performed pursuant to or related to this Agreement or a Project hereunder; and 

 

	 	ii.	necessary for the performance of a Project. 

  

	 	b.	“Foreground Intellectual Property” means Intellectual Property that is discovered, created or reduced to practice in the performance of a Project. 

 

	 	c.	“Intellectual Property” (or “IP”) means all intellectual property, including technical information, know-how, models, drawings, specifications, prototypes, inventions and software.

  

	 	d.	“University Foreground Intellectual Property” means Intellectual Property that is discovered, created or reduced to practice by University personnel in the performance of a Project. 

 

	 	e.	“University personnel” shall include but not necessarily limited to the Principal Investigator (“PI”) and University employees, subcontractors, consultants, technicians, students, post-docs
and visiting scientists. Other than the Sponsor or by written consent of the Sponsor, the University shall not have anyone other than University personnel work on the Project. 

 

	 	2.2	Ownership 

  

	 	a.	Background Intellectual Property of a Party shall remain the exclusive property of such Party. 

  

	 	b.	The University shall own all University Foreground Intellectual Property. 

  

	 	c.	Subject to all of the terms and conditions of this Agreement and the License Agreement (including section 7.2 of the License Agreement) and the agreement of any assignee to be bound hereby in writing, the University may
assign its interest in University Foreground Intellectual Property according to the University’s applicable policies and procedures upon prior notice and prior written consent by the Sponsor, such consent not to be unreasonably withheld.

  

	 	2.3	Disclosure of Inventions: The Principal Investigator will disclose any University Foreground Intellectual Property to the University in accordance with the University’s Inventions Policy, and such disclosure
will be communicated to the Sponsor promptly and in reasonably sufficient detail to permit assessment by Sponsor. University’s obligation under this Article 2.3 will not be satisfied by submission of any report as required under Article 1.6 of
this Agreement. 

  
 The Governing Council of the
University of Toronto 
 Protagenic Therapeutics, Inc. 

  
 Page 3 

	 	2.4	Sponsor’s Rights 

  

	 	a.	Option: Provided that the Sponsor is not in breach of its obligations under this Agreement, the Sponsor will have the option to obtain at its preference, either an exclusive or non-exclusive licence to use
University’s interest in University Foreground Intellectual Property in accordance with the terms of the License Agreement (the “Option”). 

  

	 	b.	Option Period: The Sponsor must indicate its intention to exercise the Option by notifying the University in writing within one hundred eighty (180) days of disclosure of the University Foreground
Intellectual Property to the Sponsor (the “Option Period”), failing which the University or its assignee(s) may offer licenses to the University Foreground Intellectual Property to third parties without further obligation to
Sponsor. Unless otherwise agreed to in writing by the Parties, the University shall be under no obligation to file, prosecute or maintain patents related to the University Foreground Intellectual Property during the Option Period. For clarity, the
University shall not disclose any of the University Foreground Intellectual Property to third parties during the Option Period. In the event Sponsor exercises the Option, University will grant to Sponsor the non-exclusive right to use University
Background Intellectual Property to the extent necessary to practice the University Foreground Intellectual Property as provided in the License Agreement. 

  

	 	c.	Representations and Warranties: Sponsor acknowledges and agrees that under the terms of the License Agreement: (i) the University Foreground Intellectual Property will be supplied and licensed to the Sponsor
on an “as is” basis; (ii) the University Foreground Intellectual Property will exclude representations and warranties as to the patentability, validity, scope or enforceability of the University Foreground Intellectual Property; and
(iii) the University Foreground Intellectual Property will exclude representations and warranties that any use of the University Foreground Intellectual Property will be free from infringement of intellectual property rights of any third party.
Notwithstanding the above, nothing in this Agreement is intended to alter or amend the terms of the License Agreement except in respect of the addition of University Foreground Intellectual Property subject to exercise of the Option.

  

	 	2.5	Research and Teaching. Notwithstanding anything in this Agreement or any resulting license, the University will retain the right to use University’s interests in all University Foreground Intellectual
Property for non-commercial research, educational and administrative purposes, without cost and in perpetuity. 

  

	 	2.6	Similar Research. Nothing in this Agreement will be construed to limit the freedom of the University or of its researchers from engaging in similar research made under other agreements with parties other than the
Sponsor as long as it does not conflict with or supersede the rights of the prior rights of the Sponsor under this Agreement or the License Agreement. 

  
 The Governing Council of the
University of Toronto 
 Protagenic Therapeutics, Inc. 

  
 Page 4 

	3.0	CONFIDENTIAL INFORMATION 

  

	 	3.1	Confidential Information. The Parties may disclose confidential information one to another to facilitate performance of this Agreement. Such information will be identified as “confidential” in writing
at the time of its transmittal, or so reduced to writing within fifteen (15) days thereafter (“Confidential Information’”), and will be safeguarded and not disclosed to third parties by the receiving Party. Confidential
Information will not include information that: 

  

	 	a.	is already known to the Party to which it is disclosed; 

  

	 	b.	is or becomes part of the public domain without breach of this Agreement; 

  

	 	c.	is obtained from third parties which have no obligations to keep confidential to the Parties to this Agreement; 

  

	 	d.	was independently developed by the receiving Party without the use of, reference to or reliance upon any of the Confidential Information of the disclosing Party. 

 

	 	3.2	Notwithstanding anything contained herein, each Party may disclose Confidential Information to its officers, employees, consultants, agents, and students on a need-to-know basis to facilitate performance of the Project,
provided that such persons agree to be bound by terms at least as restrictive as those contained herein. 

  

	4.0	PUBLICATION OF RESEARCH RESULTS 

  

	 	4.1	Review. The University will provide a copy of any proposed publication of Project research results (a “Publication”) to the Sponsor for its review at least thirty (30) days before
submission for publication or disclosure. Upon the Sponsor’s written request received within twenty (20) days of the Sponsor’s receipt of the Publication or intended disclosure, the University will, at the Sponsor’s
option: 

  

	 	a.	delete identifiable references to any Confidential Information provided by the Sponsor from the proposed Publication or intended disclosure; 

 

	 	b.	if the Sponsor has exercised the Option, delay publication of the Publication up to sixty (60) additional days to enable the Sponsor to file; in the name of the Intellectual Property owner or its assignee(s),
patent application(s) for any Intellectual Property that would be publicly disclosed in the Publication. 

  

	 	4.2	Academic Progression: Except in respect of Article 4.1(a), nothing in Article 4.1 will impose restrictions on the content or handling, for academic purposes, of the thesis of any Project
participant. 

  

	 	4.3	Disclosure of Research Results. Subject to Article 4.1, the University reserves on behalf of itself, the Principal Investigator and all other Project participants the right to disseminate information or
otherwise publish the research results arising in performance of the Project. The Sponsor’s support of the Project will be acknowledged in all such publications. 

  
 The Governing Council of the
University of Toronto 
 Protagenic Therapeutics, Inc. 

  
 Page 5 

	5.0	TERM AND TERMINATION 

  

	 	5.1	Term. This Agreement will enter into force as of the Effective Date and will terminate on 31 March 2015 (“Term”) unless sooner terminated in accordance with Article 5.2 below, or upon the written
agreement of the Parties. 

  

	 	5.2	Termination. This agreement may be terminated as follows: 

  

	 	a)	Sponsor may terminate this Agreement upon sixty (60) days written notice to University. In the event of termination, the University will be entitled to credit for work performed hereunder before termination
including the University’s non-cancellable costs incurred by University prior to the date of notice of termination, and the Sponsor will be entitled to a return of the balance of any advance payment; 

 

	 	b)	by the Sponsor upon giving sixty (60) days written notice to the University if, in the reasonable judgment of the Company, the research program is no longer technically or commercially feasible; 

 

	 	c)	written notice to the University if, at any time during the Term or any extension thereof, the parties are unable to agree on the terms of an amendment to the Research Program; 

 

	 	d)	by the Sponsor immediately upon giving written notice to the University if (i) the Sponsor does not accept the replacement Principal Investigator nominated by the University or (ii) if no replacement is
nominated within (14) days of the date on which Dr. Lovejoy become unavailable; 

  

	 	e)	by the Sponsor upon giving thirty (30) days written notice to the University if a research milestone has not achieved within the time period specified in the Research Project; or, 

 

	 	f)	by University or the Sponsor upon giving thirty (30) days written notice to the other if University is in default of fulfilling any of its material obligations under this Agreement and such default has not been
cured within such thirty (30) days notice period. 

  

	 	5.3	Effect of Termination. The provisions of Articles 1.4, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0 and 7.0 will survive termination or expiration of this Agreement in accordance with their terms. 

 

	6.0	 	LIABILITY AND INDEMNITY 

  

	 	6.1	Limitation of Liability. Neither Party will be liable for any delays in the performance of its obligations under this Agreement resulting from circumstances or causes beyond its reasonable control, and in no case
will the Parties be liable for loss of business or profit or other indirect or consequential damages. 

  

	 	6.2	 Indemnity. The University will indemnify and save harmless the Sponsor against all costs, suits or claims on account of injuries (including
death) to persons participating in the Project or to damage to University property caused by the wilful or negligent act or omission of personnel of University during the performance of this Agreement. The Sponsor will

  
 The Governing Council of the
University of Toronto 
 Protagenic Therapeutics, Inc. 

  
 Page 6 

	 	
indemnify and save harmless the University and its employees, students and agents against all costs, suits or claims on account of injuries (including death) to persons participating in the
Project or to damage to property caused by agents or personnel of the Sponsor during the performance of this Agreement or resulting from the use by the Sponsor or its affiliates, its customers or licensees of any deliverable or intellectual property
developed under this Agreement. 

  

	7.0	MISCELLANEOUS 

  

	 	7.1	Use of Names. Neither Party will use the name of the other Party, or of any member of the other Party’s personnel, in any advertising or publicity without the prior written approval of the other Party’s
authorized representative. However, both Parties may make the following information a matter of public record: name of Principal Investigator; Principal Investigator’s department; University’s name; Sponsor’s name; Project title;
Project duration; and, contract value. 

  

	 	7.2	Independent Parties. The Parties are independent parties and nothing in this Agreement will constitute either Party as the employer, principal or partner of or joint venturer with the other Party. Neither Party
has any authority to assume or create any obligation or liability, either express or implied, on behalf of the other Party. 

  

	 	7.3	Notices. Notices under this Agreement will be sent to the Parties as follows or to such other person as a Party may designate in writing: 

For Technical and Scientific Matters: 
  

							
	 	  	 To University:
	  	 To Sponsor:
	  	 
	Name:	  	Prof. David Lovejoy	  	Robert Ziroyan	  	Garo Armen
	Department:	  	Dept. of Cell and Systems Biology	  	Protagenic Therapeutics Canada(2006), Inc.	  	Protagenic Therapeutics Inc.
	Address:	  	25 Harbord Street	  	22 Elkhorn Drive, Suite 424	  	149 5th Avenue, Suite 500
	City, Province/State:	  	Toronto, ON	  	Toronto, ON	  	New York, NY
	Postal/Zip Code, Country:	  	M5S 3G5	  	M2K 1J4	  	10010
	Tel:	  	416-946-7259	  	416-500-3305	  	212-994-8202
	Email:	  	David.lovejoy@utoronto.ca	  	rziroyan@protagenic.com	  	armen@agenusbio.com

  
 The Governing Council of the
University of Toronto 
 Protagenic Therapeutics, Inc. 

  
 Page 7 

 For Legal and Administrative Matters: 

 

					
	 	  	 To University:
	  	 To Sponsor:

	Name:	  	Colleen Burke	  	Robert Ziroyan
	Department:	  	Innovations & Partnerships Office (IPO), University of Toronto	  	Protagenic Therapeutics Canada (2006), Inc.
	Address:	  	 Banting Institute
 100 College Street, Suite
413
	  	22 Elkhorn Drive, Suite 424
	City, Province/State:	  	Toronto, ON	  	Toronto, ON
	Postal/Zip Code, Country:	  	M5G 1L5 Canada	  	M2K 1J4
	Tel:	  	416-978-3648	  	416-500-3305
	Email:	  	Innovations.partnerships@utoronto.ca	  	rziroyan@protagenic.com

 For Financial Matters: 
  

							
	 	  	 To University:
	  	 To Sponsor:
	  	 
	Name:	  	Yolanda Buenaflor	  	Robert Ziroyan	  	Garo Armen
	Department:	  	 Research Oversight & Compliance Office (ROCO),

University of Toronto
	  	Protagenic Therapeutics Canada (2006), Inc.	  	Protagenic Therapeutics Inc.
	Address:	  	 McMurrich Building, F2
 12 Queen’s Park
Crescent W.
	  	22 Elkhom Drive, Suite 424	  	149 5th Avenue, Suite 500
	City, Province/State:	  	Toronto, ON	  	Toronto, ON	  	New York, NY
	Postal/Zip Code, Country:	  	M5S 1S8 Canada	  	M2K 1J4	  	10010
	Tel:	  	416-978-6464	  	416-500-3305	  	212-994-8202
	Email:	  	yolanda.buenatlor@utoronto.ca	  	rziroyan@protagenic.com	  	

  

	 	7.4	No Assignment. Except as provided for in Article 2.0, neither Party may sell, assign, encumber, licence or otherwise transfer any of its rights, duties or obligations under this Agreement without the prior
written consent of the other Party, which consent may not be unreasonably withheld. Notwithstanding the foregoing, the Company may assign its rights or obligations under this Agreement in connection with a merge or change of control or to an entity
acquiring all, or substantially all of the Company’s business or assets to which this Agreement relates without obtaining the consent of the University. 

  

	 	7.5	Successors. This Agreement binds and enures to the benefit of the Parties hereto and their respective heirs, successors and permitted assigns. 

 

	 	7.6	Interpretation. This Agreement will be governed by and construed in accordance with the laws of the Province of Ontario in Canada. In the event that a court of competent jurisdiction holds any provision of this
Agreement to be invalid, such holding will have no effect on the remaining provisions of this Agreement, which will continue in full force and effect. Headings are used for convenience only and will not be used to interpret the provisions of this
Agreement. 

  
 The Governing Council of the
University of Toronto 
 Protagenic Therapeutics, Inc. 

  
 Page 8 

	 	7.7	Entire Agreement. This Agreement is the entire agreement of the parties with respect to its subject matter and no change or modification will be valid unless it is in writing and signed by both parties.

  

	 	7.8	Counterparts. This Agreement may be executed by signatures delivered by facsimile transmission or delivered electronically in optically scanned form; and/or it may be simultaneously executed by the parties in
multiple counterparts, each of which will be considered to be an original instrument, and all of which taken together, where each Party has executed at least one counterpart, will constitute one and the same instrument. 

IN WITNESS WHEREOF by signature of their respective authorized officers, the parties agree to be bound by the terms of this Agreement. 

 

							
	 THE GOVERNING COUNCIL OF
 THE
UNIVERSITY OF TORONTO
	  	 PROTAGENIC THERAPEUTICS CANADA (2006), INC.

PROTAGENIC THERAPEUTICS, INC.

		
	  
	  	  

	Name:	  	Lino DeFacendis	  	Name:	  	Robert Ziroyan. PhD, MSc
	Title:	  	Director, Partnerships	  	Title:	  	Chief Operating Officer, President
		  	/s/ Lino DeFacendis	  		  	/s/ Robert Ziroyan
		  	  
	  		  	  

	Date:	  	April 21/15	  	Date:	  	April

  
 The Governing Council of the
University of Toronto 
 Protagenic Therapeutics, Inc. 

  
 Page 9 

 Acknowledgement: 

I, the Principal Investigator, having read this Agreement, hereby agree to act in accordance with all the terms and conditions herein and applicable University
policies, and further agree to ensure that all University participants are informed of their obligations under such terms and conditions. 
  

			
	/s/ David Lovejoy
	Name:	 	Prof. David Lovejoy
	Date:	 	April 15, 2015

  
 The Governing Council of the
University of Toronto 
 Protagenic Therapeutics, Inc. 

  
 Page 10 

 APPENDIX “A” 

Description of the Project 

April 2014 – March 31 2015 

PROJECT TITLE: 
 Teneurin C-terminal Associated Peptide
(TCAP)-mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism.” 

Duration: April 1, 2014 - March 31, 2015 

GOALS: 
  

	 	1)	Complete the elucidation of the signal transduction cascade by TCAP-1 associated with cellular energy metabolism with the goal of establishing an intracellular mechanism by which TCAP-1 exerts its effects in animals.

  

	 	2)	Efficacy of synthetic TCAP-1 on the treatment of animal models of addictive disorders, and insulin-independent glucose regulation for indications for diabetes, infertility and skeletal muscle performance.

 Background. 
 The discovery of the
teneurin C-terminal associated peptides (TCAP) were reported in 2004 by our laboratory and consisted of a family of four bioactive peptides in mammals (Qian et al., 2004). We subsequently showed that the TCAP-l paralogue was highly efficacious at
inhibiting anxiety as determined by the acoustic startle response in rats (Wang et al., 2005; Lovejoy et al., 2006; 2009). Further studies indicated that these peptides inhibited the corticotropin-releasing factor (CRF) facilitation of anxiety using
a number of behavioural models (Al Chawaf, 2007; Tan et al., 2008; 2011; 2012; Rotzinger et al., 2010). In addition, TCAP-1 could inhibit CRF-associated neuronal activation in key regions of the brain associated with emotion (Tan et al., 2009b).
Based on the inhibitory actions of TCAP-I on CRF, subsequent studies established that TCAP-I could also inhibit the CRF-induced facilitation of cocaine addiction (Kupferschmidt et al. 2011). 

Over the same period, we showed that TCAP-1 had a neuroprotective effect on neurons and was associated with neurotrophic activity (Trubiani et al., 2007, Ng
et al., 2010) and that the peptide played a role with aerobic metabolism. However, associated with these actions were increased neuronal process formation (Al Chawaf et al., 2007b: Tan et al., 2009a; 2011). The cloning of the gene, and
identification of the receptor mechanism and associated signal transduction system required for process development was recently established (Chand el al., 2012; 2013c) thereby establishing the independence of the TCAP-l system. Further studies
confirmed the evolution of the TCAP-l peptide as a distinct signalling entity (Chand et al., 2013d) that played a role in cellular metabolism. 

  
 The Governing Council of the
University of Toronto 
 Protagenic Therapeutics, Inc. 

  
 Page 11 

 Taken together, these studies indicated that TCAP-l played a major role in the regulation of cellular metabolism
and were most active in highly metabolic cells such as the brain (Chand et al., 2013b) and reproductive organs (Chand et al., 2013a). We have now established that TCAP-l increases energy production in cells by an insulin-independent increase in
glucose transport and energy transduction in both neurons and skeletal muscle, and further, may play a role in male reproductive function. 
 Therefore,
these findings indicate that TCAP-l likely exerts its neuroprotective and neurological effects by increasing energy usage in brain cells to effectively increase the stress threshold of these cells. Further studies indicate that it likely has similar
effects throughout the organism to increase the efficiency of glucose and energy metabolism. Thus, this peptide has applications to a wide variety of pathological disorders associated with energy metabolism that include neurological pathology,
glucose availability such as diabetes, reproductive disorders such as infertility and muscular disorders. 
 Cited References: 

Al Chawaf A, Xu K, Tan L, Vaccarino F, Lovejoy, DA, Rotzinger S (2007a) Corticotropin-releasing factor behaviours are modulated by intravenous
administration of teneurin C-terminal associated peptides. Peptides 28, 1406-1415. 
 Al Chawaf A, St. Amant, K, Belsham DD, Lovejoy DA
(2007b) Regulation of neurite outgrowth in immortalized hypothalamic cells and hippocampal primary cultures by teneurin C-terminal associate peptide-l (TCAP-I). Neuroscience 144, 1241-1254. 

Chand D, Colacci M, Dixon K, Kollara A, Brown TJ, Lovejoy DA (2013a) C-terminal region of teneurin-l co-localizes with the dystroglycan complex in the
seminiferous tubules and epididymis of the adult mouse testes and regulates testicular size and testosterone production. Journal of Histology and Cell Biology 141, 191-121. 

Chand D, Casatti C, Bittencourt JC, Kollara A, Brown TJ, Lovejoy DA (2013b) Expression and localization of the Teneurin C-terminal Associated Peptide
(TCAP-1) in the adult mouse (Mus musculus) brain. Journal of Comparative Neurology (submitted) 
 Chand D, Casatti CA, de Lannoy L, Song L, Kollara
A, Barsyte-Lovejoy D, Brown TJ, Lovejoy DA (2013c) C-terminal processing of the teneurin proteins: Independent actions of a teneurin C-terminal associated peptide in hippocampal cells. Molecular and Cellular Neuroscience 52, 38-50. 

Chand D, de Lannoy, L, Tucker RP, Lovejoy DA (2013d) Origin of chordate peptides by horizontal protozoan gene transfer in early metazoans and protists:
Evolution of the teneurin C-terminal associated peptides. General and Comparative Endocrinology 188, 144-150. 

  
 The Governing Council of the
University of Toronto 
 Protagenic Therapeutics, Inc. 

  
 Page 12 

 Chand D, Song L, de Lannoy L, Barsyte-Lovejoy D, Ackloo S, Boutros PC, Evans K, Belsham DD, Lovejoy DA
(2012) C-terminal region of teneurin-l co-localizes with dystroglycan and modulates cytoskeletal organization through an ERK-dependent stathmin- and filamin A-mediated mechanism in hippocampal cells. Neuroscience 219, 255-270 

Kupferschmidt D, Lovejoy DA, Rotzinger S, Erb S (2011) Teneurin C-terminal associated peptide (TCAP)-l blocks the effects of corticotropin-releasing
factor (CRF) on the reinstatement of cocaine seeking and expression of cocaine induced behavioral sensitization British Journal of Pharmacology 163, 574-583 

Lovejoy DA, A1 Chawaf A, Cadinouche, A. (2006) Teneurin C-terminal associated peptides: An enigmatic family of neuropeptides with structural similarity
to the corticotrophin releasing factor and calcitonin family of peptides. General and Comparative Endocrinology 148, 299-305 
 Lovejoy DA, Rotzinger S,
Barsyte-Lovejoy, D (2009) Evolution of complementary peptide systems: Teneurin C-terminal associated peptide (TCAP) and corticotropin-releasing factor (CRF) superfamilies. Annals of the New York Academy of Sciences. 1163, 215-220. 

Ng. T, Chand D, Song L, Watson JD, Boutros PC, Barsyte-Lovejoy D, Belsham DD, Lovejoy DA (2011) Identification of a novel Brain Derived Neurotrophic
Factor (BDNF)-inhibitory factor: Regulation of BDNF by Teneurin C-terminal Associated Peptide (TCAP)-l in immortalized embryonic mouse hypothalamic cells Regulatory Peptides 174, 79-89. 

Qian X, Barsyte-Lovejoy D, Chewpoy RH, Wang L, Gautam N, Wang N, Al Chawaf A, Lovejoy DA (2004) Characterization of teneurin C-terminal associated
peptide (TCAP)-3 from rainbow trout hypothalamus. General and Comparative Endocrinology 
 137, 205-216 

Rotzinger S, Lovejoy DA, Tan L (2010) Behavioral effects of neuropeptide ligands in rodent models of depression and anxiety. Peptides 31, 736-756 

Tan LA, Al Chawaf A, Vaccarino FJ, Boutros, JC, Lovejoy DA (2011) Teneurin C-terminal associated peptide (TCAP)-1 increases dendritic spine density in
hippocampal neurons and decreases anxiety-like behaviors in rats. Physiology and Behavior 104, 199-204. 
 Tan LA, Chand D, De Almeida R, Xu M, Colacci M,
de Lanno, L, Lovejoy DA (2012) Modulation of neuroplastic changes and corticotropin-releasing factor associated behaviour by a phylogenetically ancient and conserved peptide family. General and Comparative Endocrinology. 176, 309-313. 

Tan L, Lovejoy DA (2009a) Neuroprotection, neuronal remodeling, and anxiety-like behaviour: The role of the teneurin and teneurin C-terminal associated
peptide (TCAP) system in the hippocampus. American Journal of Neuroprotection and Neuroregeneration. 1: 3-10 
 Tan L, Xu K, Vaccarino FJ, Lovejoy DA,
Rotzinger S (2009b) Teneurin C-terminal associated peptide (TCAP)-l attenuates corticotropin-releasing factor (CRF)-induced c-Fos expression in the limbic system and modulates anxiety behaviour in male Wistar rats. Behavioural Brain Research
201, 198-206 

  
 The Governing Council of the
University of Toronto 
 Protagenic Therapeutics, Inc. 

  
 Page 13 

 Tan L, Xu K, Vaccarino F, Lovejoy DA, Rotzinger S (2008) Repeated intracerebral teneurin C-terminal
associated peptide (TCAP)-l injections produce enduring changes in behavioral responses to corticotropin-releasing factor (CRF) in rat models of anxiety. Behavioural Brain Research 188, 195-200. 

Trubiani G, Al Chawaf A, Belsham DD, Barsyte-Lovejoy D, Lovejoy DA (2007) Teneurin carboxy (C)-terminal associated peptide-1 inhibits
alkalosis-associated necrotic cell death by stimulating superoxide dismutase and catalase activity in immortalized mouse hypothalamic cells. Brain Research 1176.27-36. 

Wang L, Rotzinger S, Barsyte-Lovejoy D, Qian X, Elias CF, Bittencourt JC, De Cristofaro A, Wang NC, Belsham D, Vaccarino F, Lovejoy DA (2005) Teneurin
proteins possess a carboxy terminal corticotropin-releasing factor-like sequence that modulates emotionality and neuronal growth. Molecular Brain Research 133, 253-265 

Research Program Overview 
 The goal of this research
program is to provide confirmation that TCAP-l can be used to treat these disorders. This will be done within the scope of four main research projects: 
  

	 	1.	Metabolism: Investigation of the role of TCAP-1 with respect to diet and type II diabetes. 

  

	 	2.	Establish proof of concept data that TCAP-l treatment improves skeletal muscle performance. 

  

	 	3.	Cocaine addiction. 

  

	 	4.	Regulation of TCAP-1 with respect to infertility. 

 Description of Projects 

1. Glucose/Metabolism Project 

Goto-Kakizaki (GK) Hyperglycaemia study: These studies will test whether TCAP-1 administration can rescue the hyperglyaemic effect inherent in this
animals. In the first study, a single dose of TCAP-1 will be administered to determine if plasma glucose will be reduced. In addition, samples of pancreas, muscle, liver, brain and testes will be taken from each animal. Metabolic hormones wi1l be
examined. In the second study, repeated doses of TCAP-l will be given to determine long-term effects of the peptide. 
 Zucker Diabetic Obese
Hyperglycaemia study: These studies will test whether TCAP-l administration can rescue the hyperglyaemic effect associated with a high calorific diet in this animals. In the first study, a single dose of TCAP-1 will be administered to determine
if plasma glucose will be reduced. In addition, samples of pancreas, muscle, liver, brain and testes will be taken from each animal. Metabolic hormones will be examined. In the second study, repeated doses of TCAP-l will be given to determine
long-term effects of the peptide . 

  
 The Governing Council of the
University of Toronto 
 Protagenic Therapeutics, Inc. 

  
 Page 14 

 In vitro Studies: A combination of in vitro models using immortalized cell culture and tissue sections
will be used to ascertain the molecular mechanism TCAP-l utilizes to regulate energy production. This will be aimed at establishing the independence of TCAP-1 from the insulin signal transduction pathway and will support the studies associated with
the Metabolism project (above). Moreover, these studies will provide information to interpret safety studies are part of the IND enabling program. Most of these studies are now complete for neurons. Similar studies are being carried out in skeletal
muscle cells. 
 Additional in vitro studies utilizing recombinant DNA methods to express TCAP in immortalized cells will be used to determine how TCAP is
regulated and processed and is expected to provide insight into the type of pathologies that TCAP is involved in. Currently, the specific mRNA has been cloned and a mouse-based knockdown of TCAP-1 will be prepared. This model will be useful to
assess all elements of TCAP-1 action including neurological and behavioural regulation, metabolism and infertility. 
 Blood hormone/metabolite
study: The goal of these studies is to assess the acute actions of TCAP-l on metabolic parameters. In this study, rats will be given either vehicle, or one of two doses of TCAP-1 (25 or 250 pmols). Blood will be collected at 0, 15, 30, 60, 120
and 240 minutes later. Insulin, glucose, triglycerides, glucagon, leptin will be determined for each time point. 
 2. Skeletal Muscle
Performance (associated with part 1 above) 
 Previous studies in mice have established that TCAP-l changes
muscle fiber density, and is associated with insulin-independent glucose uptake. Moreover, TCAP-l immunoreactivity and binding is concentrated in regions of the neuromuscular junction. New studies are designed to establish how muscle fiber growth is
regulated by TCAP-l both in vitro and in vivo. In vivo studies will be used to establish how TCAP-1 treatment can regulate muscle contractility and determine whether tissue damage is reduced by TCAP-1. 

3. Fertility 
 The actions of
TCAP-l on male mice reproduction will be investigated by examining morphological and physiological changes that occur in the testes and associated tissues following TCAP-l treatment. In addition, a previously developed immunoassay will be used to
investigate the expression of TCAP-1 immunoreactivity in human clinical samples. 
 4. Cocaine addiction 

In vivo Studies: The effect of TCAP-l using intravenous administration under a variety of conditions will be used to determine the efficacy of TCAP-1 on
the inhibition of cocaine seeking reinstatement in rats. These studies are currently underway in the laboratory of Dr. Suzanne Erb. Further studies will be aimed at determining the molecular and neural pathways by which this mechanism occurs.
Based on previous data, we hypothesize that TCAP-1 regulates cocaine addiction by altering the dopaminergic pathway associated with reward. Thus these new studies are aimed at determining the co-localization of the TCAP-1 system with that of the
dopaminergic pathway. 

  
 The Governing Council of the
University of Toronto 
 Protagenic Therapeutics, Inc. 

  
 Page 15 

 In vitro Studies: Currently, an in vitro model is being developed to determine if TCAP-l can regulate
dopamine receptors. Pending the results of these studies, TCAP-l and cocaine will be used to treat rats and determine if TCAP-l regulates elements of the dopaminergic system in vivo. 

  
 The Governing Council of the
University of Toronto 
 Protagenic Therapeutics, Inc. 

  
 Page 16 

 APPENDIX “B” 

Project Budget 
  

							
	 Item
	  	Particular	  	Total	 
	 Total Direct Costs
	  		  	 	65,630	  
	 Indirect Costs at 15%
	  		  	 	9,845	  
		  		  	  
	  
	 
	 Total
	  		  	 	75,475	  
		  		  	  
	  
	 

 Payment schedule: 

University of Toronto will submit invoices to Sponsor according to the following schedule: 

Upon execution of the Agreement: $25,000 
 May 31, 2015:
$25,000 
 June 30, 2015: $25,475 
 Payment method:

 Sponsor will pay via electronic wire transfer. 

  
 The Governing Council of the
University of Toronto 
 Protagenic Therapeutics, Inc. 

  
 Page 17 

 APPENDIX “C” 

Please return a signed original of this Undertaking to Colleen Burke at Innovations & Partnerships Office, 100 College St., Suite 413. Colleen Burke
can be reached at 416-946-7342 for information about the Research Agreement. 
 3/5/2013 

PRINCIPAL 

INVESTIGATOR’S UNDERTAKING 
 RE:
Contract (“the Research Agreement”) between The Governing Council of the University of Toronto and Protagenic Therapeutics Canada (2006), Inc. and Protagenic Therapeutics, Inc. for a project entitled “Determination of the cellular
activation mechanism of teneurin C-terminal associated peptide (TCAP-1) and its relationship to organismal energy regulation” (the “Project”) and Technology License Agreement entered into between the Parties on July 21, 2005 as
amended (the “License Agreement”) 
 UNDERTAKING 

I have read and received a copy of the “Research Agreement” and the “License Agreement” and agree with the terms and conditions contained
therein. I will ensure that the Project is performed as outlined in the Research Agreement and will meet the obligations as specified in the Research Agreement and the License Agreement. I will authorize all project expenditures as outlined in the
Research Agreement and the normal procedures and practices of the University, and in all matters will follow normal University policies and practices where they are not replaced by specific conditions of the Research Agreement or the License
Agreement. 
 I will inform each person working on the Project, whether or not paid from Research Agreement funds (the “Participant”), of the
Participant’s obligations under the Research Agreement and the License Agreement, and ensure that each Participant signs a Confidential Information and Intellectual Property Agreement (“IP Agreement”). I understand that any person who
does not wish to sign an IP Agreement may not participate in the Project unless advised otherwise by the Innovations & Partnerships Office. 
 A
list of Participants is provided on the reverse and a signed IP Agreement for each Participant is attached. I have indicated on the reverse if any Participant’s work involves his or her thesis. If any person not listed on the reverse commences
work on the Project, I will submit an additional IP Agreement for such person promptly upon his or her commencement of work. 
  

	
	/s/ David A. Lovejoy
	Name: David A. Lovejoy
	Principal Investigator
	Date: April 15, 2015

  

							
	 ACKNOWLEDGEMENT

 
	  		  	
	Name:	  		  		  	
		  	Chair, Department of Cell and Systems Biology	  		  	
	Date:	  	 	  		  	
                        More®

  

  
 The Governing Council of the
University of Toronto 
 Protagenic Therapeutics, Inc. 

  
 Page 18 

 Project Participants 

 

					
	RE:	  	Agreement with Sponsor:	  	Protagenic Therapeutics Canada (2006), Inc. and Protagenic Therapeutics, Inc.
			
		  	for Project:	  	Determination of the Cellular Activation mechanism of teneurin C-terminal associated peptide (TCAP-1) and its relationship to organismal energy relation.
			
		  	by Principal Investigator:	  	David Lovejoy

 The following is a complete list of all persons who are working on the Project, whether or not paid from Research Agreement
funds, as of April 15, 2015. 
  

					
	 Name
	  	 Status

(student, postdoc, RA, technician, etc.)
	  	Involves Thesis
	Rebecca Woelfle	  	MSc student	  	yes
	Andrea D’Aquila	  	PhD student	  	yes
	Mia Husic	  	MSc student	  	yes
	Tea Pavlovic	  	PhD student	  	yes
	Dr. David Hogg	  	Postdoctoral Fellow	  	no
	[[Participant 6]]	  		  	
	[[Participant 7]]	  		  	
	[[Participant 8]]	  		  	
	[[Participant 9]]	  		  	
	[[Participant 10]]	  		  	
	[[Participant 11]]	  		  	
	[[Participant 12]]	  		  	
	[[Participant 13]]	  		  	
	[[Participant 14]]	  		  	
	[[Participant 15]]	  		  	
	[[Participant 16]]	  		  	
	[[Participant 17]]	  		  	

  
 The Governing Council of the
University of Toronto 
 Protagenic Therapeutics, Inc. 

  
 Page 19EX-10.20(ii)

 Exhibit 10.20(ii) 

AMENDING AGREEMENT 

This Amending Agreement is made effective the 1st day of April, 2015 (the “Effective
Date”). 
 BETWEEN: 

THE GOVERNING COUNCIL OF THE UNIVERSITY
OF TORONTO 
 (the “University”) 

- and - 

PROTAGENIC THERAPEUTICS CANADA (2006), INC, 

PROTAGENIC THERAPEUTICS INC. 

(the “Sponsor”) 

(Individually a “Party” and collectively the “Parties”) 

WHEREAS the Parties entered into a Technology License Agreement effective July 21, 2005, as amended, (collectively, the “License
Agreement”) 
 AND WHEREAS the Parties under said License Agreement entered into a Sponsored Research greement effective April 1st, 2014 (the “Research Agreement”) for the performance of a research project entitled “Teneurin C-terminal Associated Peptide (TCAP)-mediated stress attenuation in vertebrates:
Establishing the role of organismal and intracellular energy and glucose regulation and metabolism” (the “Project”); 
 AND WHEREAS
the parties now wish to amend the Research Agreement by reference herein; 
 NOW THEREFORE the Parties hereby agree as follows: 

 

	1.	Definitions. Except as otherwise defined herein, any capitalized terms used in this Amending Agreement shall have the meanings prescribed by the Research Agreement. 

 

	2.	Amendments. 

  

	 	a.	Section 5.1 is hereby deleted in its entirety and replaced with the following: 

 5.1
Term. This Agreement will enter into force as of the Effective Date and will terminate on 31 March 2016 (“Term”) unless sooner terminated in accordance with Article 5.2, or upon the written agreement of the Parties. 

 

	 	b.	Appendix “A” Description of the Project, is hereby amended to include “Appendix A-1” attached hereto. 

 

	 	c.	Appendix “B” Project Budget is hereby amended to include “Appendix B-1” attached herto. 

  
 1 

	3.	Counterparts. This amending agreement may be executed by signatures delivered by facsimile transmission or delivered electronically in optically scanned form; and/or it may be simultaneously executed by the
parties in multiple counterparts, each of which will be considered to be an original instrument, and all of which taken together, where each party has executed at least one counterpart, will constitute one and the same instrument. 

 

	4.	General. The provisions herein shall supersede and replace all conflicting provisions and subject matter otherwise contained in the Research Agreement, and in the event of any contradiction or conflict between
the Research Agreement and this Amending Agreement, this Amending Agreement shall prevail and govern the contractual relations and all other obligations and rights between the Parties hereto. All other terms of the Research Agreement shall remain
unchanged and in full force and effect. This Amending Agreement shall be governed by, and interpreted and enforced in accordance with the laws in force in the Province of Ontario and the federal laws of Canada applicable therein. 

IN WITNESS WHEREOF by signature of their respective authorized officers, the parties agree to be bound by the terms of this Amending Agreement. 

 

									
	 THE GOVERNING COUNCIL OF

THE UNIVERSITY OF TORONTO
	 		 	 PROTAGENIC THERAPEUTICS CANADA (2006), INC.

PROTAGENIC THERAPEUTICS, INC.

					
		 	 /s/ P. Lino DeFacendis
	 		 		 	 /s/ Robert Ziroyan

	NAME:	 	P. Lino DeFacendis	 		 	NAME:	 	Robert Ziroyan
	TITLE:	 	Director, Partnerships	 		 	TITLE:	 	President and Chief Operating Officer
	DATE:	 	Sept. 28, 2015	 		 	DATE:	 	September 23, 2015

 Acknowledgement: 
 I, the
Principal Investigator, having read this Agreement, hereby agree to act in accordance with all the terms and conditions herein and applicable University policies, and further agree to ensure that all University participants are informed of their
obligations under such terms and conditions. 
  

			
		 	 /s/ David Lovejoy

	NAME:	 	David Lovejoy
	DATE:	 	September 29, 2015

  
 2 

 Appendix “A-1” 

Description of the Project 

April 2015 – March 2016 
 Prepared by
David A. Lovejoy, August 2015 
 Project 2015-1: Effect of TCAP on Glucose Regulation and Type II Diabetes 

2015-1-A: TCAP actions of Glucose in the brain 

This project was designed to establish proof of principal that TCAP could regulate glucose action in the brain. This was a 5-year project to establish both in
vitro and in vivo mechanisms of how TCAP acts to increase glucose transmission in the brain and how it affects organismal glucose, insulin and glucagon levels. 

2015-1-A1: Brain Glucose Completion: Following from studies with Molecular Imagining, Inc in 2014, this project was aimed at finalizing completing the
blood biochemistry and hematology studies. [complete] 
 2015-1-A2: Brain Glucose, Mechanism: Further studies were aimed at establishing the signal
transduction mechanism of TCAP in the cell line models used for the glucose study. Further studies were aimed at establishing that TCAP-1 had a distinct action on intracellular calcium flux.[complete] 

2015-1-B: TCAP actions of glucose in the muscle 

Following from the original observation that TCAP-1 could affect glucose regulation in muscle, further studies were performed to establish an in vivo action in
muscle. 
 2015-1-B1: In vivo proof of concept: SC administered rats showed significantly improved muscle tension and recovery from exertion.
[complete] 
 2015-1-B2: Immunohistochemistry: Tissues collected from the animals in the above study will be assessed for water and glycogen
accumulation, and fiber type. This study has already established that water is significantly increased in affected muscle. Previous studies have established that TCAP acts in part through dystroglycan actions which have been implicated with
aquaporin regulation. Aquaporin-4 is the dominant water transporter in muscle and studies are currently underway to establish how this protein is regulated. [partially complete. Expected completion Oct, 2015] 

2015-1-B3: Pathology. Muscle tissue will be assessed for damage. Sectioning has been completed. Final pathology assessment expected to be completed
Sept-Oct 2015) [in progress] 
 2015-1-B4: Ion Regulation. In vivo studies indicated that the increased recovery from muscle fatigue is likely due to
increased calcium and possibly sodium and or potassium flux. This will be assessed using differentiated C2C12 cells. The model and methods have been developed. Studies are currently underway to assess these ion fluxes [expected completion Oct-Nov,
2015] 
 2015-1-B5: Wound Healing. Based on the findings of the pathological studies, to be performed, as well as novel studies indicating increased
growth of the C2C12 myocyte model, and previous studies indicating a role of TCAP in cell protection, studies are planned to assess proof of principal for wound healing. This is expected to begin Jan 2016. Should this prove successful, this will
generate new IP and a new research project. [completion expected May 2016] 
 2015-1-B6: Long term studies: To date, the actions of TCAP with respect
to glucose regulation in brain and muscle have been performed with acute administration. This study will include both the actions of TCAP with respect to type II diabetes and muscle action in a single study. [to begin Autumn 2015, results expected
Jan-Feb 2016] 

 Project 2015-2 Structure Function Studies 

This project is designed to assess the binding affinity, signal transduction mechanisms of the key TCAP peptides and their truncated analogues with the goal to
produce novel variants and to protect the key amino acid motifs for patent applications. 
 2015-2-A Bioactivity 

This component focuses on the signal transduction mechanisms of the endogenous TCAP peptides 

2015-2-A1: Calcium Flux. Calcium flux will be measured electrophysiologically using various pharmacological agonists and antagonists of endoplasmic
reticulum, mitochondrial and plasma membrane channels. To date, studies for mouse TCAP-1 have been completed. Mouse TCAP-3, and human TCAP-1 are expected in the next month. [completion Jan-Mar 2016] 

2015-2-A2: Potassium. Plasma membrane potassium channels will be measured using patch-clamping electrophysiology methods. Studies have begun.
[Completion Jan-Mar 2016] 
 2015-2-A3: IP3, DAG. This signal transduction system is associated with the receptors (latrophilins). Mouse TCAP-1 has
been assessed in five different cell lines. Further studies, currently in progress will assess the actions of the other key endogenous peptides [Completion expected Nov-Dec 2015] 

2015-2-A4: MEK, ERK: This signal transduction system is associated with the dystroglycans which associate with the latrophilins. Mouse TCAP-1 has been
assessed in three different cell lines. Further studies, currently in progress will assess the actions of the other key endogenous peptides [Completion expected Nov-Dec 2015] 

2015-2-A5: cAMP, PKA. Previous studies established that mouse TCAP-1 and 3 activate this signal transduction system, and reports in the literature
indicate the receptor can be associated with this system. Additional homologues will be investigated. [Completion Early 2016] 
 2015-2-A6: Glucose
ATP. Previous studies have established that mouse TCAP-1 increases glucose transport in the cells resulting in increased mitochondrial ATP activity. Further studies on the actions of mitochondria will establish the role of TCAPs on mitochondrial
activity. Methods are currently be evaluated [completion early 2016] 
 2015-2-B Receptor Binding 

Both the full-length and functional domains of the receptor will be over-expressed in cell lines and the binding ability of TCAP variants will be assessed.

 2015-2-B1 Full length latrophilin: Currently several methods have been employed to express the full length receptor. Data indicates increased
co-localization of tagged TCAP with the receptor. The sensitivity of this method will be improved. [completion: Dec 2015] 
 2015-2-B2: Hormone binding
domain: The latrophilins possess a conserved hormone binding domain. This region has been transgenetically over expressed in cell lines and shown to bind with the putative mature endogenous mouse TCAP-1 (1-41) but not the prohormone confirming
that the synthetic form of TCAP-1 binds to the latrophilin receptor. [Completed] 
 2015-2-C: Analogue Development 

To date, several truncated variants of TCAP-1 have been developed. This study is designed to assess the efficacy of each analogue and design novel sequences
with the goal of developing a shorter and more efficacious synthetic form 
 2015-2-C1: Human TCAP-1. Synthesis is completed. Evalution of the
sequence currently in progress. 
 2015-2-C2: Mouse TCAP-3. Synthesis is completed. Bioactivity testing to being Oct 2015 

 2015-2-C3: Human TCAP-3. Sequence defined. Synthesis is expected to being early 2016. 

2015-2-C4: Truncated analogues. First set of truncated variants synthesized. Partial activity assessed for the mouse TCAP-1 (9-37) variant. 

Project 2015-3: TCAP and infertility 
 Previous studies
have established that TCAP-1 has a regulatory action of sex steroids and gonadal morphology in mice. However, the studies were equivocal in that it was not clear whether TCAP-1 had a direct action on the gonads (i.e. gonadotropin-independent) or
were acting at the level of GnRH production, release and synthesis at the hypothalamic level. Moreover, in both male and female tissues TCAP-1 and teneurin immunoreactivity was highly expressed indicating a number of physiological roles. 

2015-3-A: Male Reproduction 
 These studies are
designed to establish the mechanism by which TCAP-1 regulates reproductive function. 
 2015-3-A1: In vivo, LH, T: This study was a follow up to a
previous study showing that TCAP-1 could regulate testosterone production in mice. In this study the regimen was changed to reflect current efficacy studies of TCAP and blood was sampled to determine if testosterone and LH was regulated in a
pulsatile manner. Testosterone studies have been completed. LH studies are currently in progress. [Completion Dec 2015] 
 2015-3-A2: In vitro LH, T:
An in vitro model has been developed to examine the molecular and cellular actions of TCAP in leydig and sertoli cells. Currently, the signal transduction and cellular expression of key molecular components have been completed. LH measurements will
begin within the next two months. 
 2015-3-A3: Sperm motility, ex vivo: Based on previous studies, TCAP-1 is not expected to have an appreciable
effect on sperm motility in normal animals. Models are currently being assessed for an appropriate in vivo model. Studies are expected to being in 2016. 

2015-3-A4: Sperm motility, in vivo: Based on previous studies, TCAP-1 is not expected to have an appreciable effect on sperm motility in normal
animals. Models are currently being assessed for an appropriate in vivo model. Studies are expected to being in 2016. 
 2015-3-B: Female Reproduction

 These studies are designed to complete previous studies on the expression of TCAP-1, teneurin, dystroglycan and latrophilin expression in the
female reproductive tract. 
 2015-3-B1: Immunohistochemistry: Normal female mice will be assessed for dystroglycans and latrophilins in reproductive
tissues. 
 Project 2015-4 Neuroprotection 
 Based on
previous studies, TCAP-1 plays a significant role in the protection of neuronal cells. These studies will be aimed at delineating the mechanism by which this occurs. 

2015-4-A TCAP variants 
 Various TCAP peptides will
be used to assess different models of cell protection in neuronal cell lines. 
 2015-4-A1 In vitro assessment: TCAP will be used to examine ROS and
glutamate actions in hypothalamic, hippocampal and midbrain cell models. 

 Project 2015-5 Behaviour 

Numerous previous studies have indicated a number of actions of TCAP-1 on behaviour in rodents. Our recent understanding of the mechanisms of TCAP-1 have
allowed us to re-evaluate previous unpublished behavioural studies to develop a new understanding of TCAP with respect to behaviour. Based on these studies, further studies are planned to provide a greater understanding of how TCAP affects behaviour
and what could be expected in the clinic. 
 2015-5-A Learning 

To date, no studies have been performed on learning behaviour, per se. Some studies indicate that TCAP could be affecting motivational behaviours, which could
manifest as a change in learning behaviour. Further tests using standardized models are planned. 
 2015-5-A1: Morris water maze: Locational learning
has been suggested by previous in vivo studies indicating that key regions of the hippocampus associated with direction are modified by TCAP. This study will provide further evidence of these observations. 

2015-5-A2: T-maze: This will be a modification of the previous H-maze test completed earlier to determine if the effects will be similar. 

2015-5-A3: Passive avoidance: This will build on previous studies indicating that TCAP may influence the avoidance of noxious events. 

2015-5-B Depression 
 Previous studies,
particularly the sucrose administration and forced swim test indicates that TCAP-1 decreases depressive like behaviours. A further test is suggested to provide confirmation. 

2015-5-B1 Tail suspension. This is one of the ‘gold standard’ tests for depression, and has not been previously performed. 

Personnel 
 Dr. David Hogg: Post
Doctoral Fellow: Dr. Hogg is a neurophysiologist with exception creative problem solving skills. He developed the electrophysiological methodology for analyzing TCAP variants in vitro and ex vivo. Moreover, he has a strong understanding of
neuroprotection and has the skill set to analyze novel analogues using a variety of methods. Although his contract ends in February, I am suggesting that he continues after that. 

Andrea D`Aquila: PhD Candidate: Although this student is exceptional and provided much input into novel intellectual property, she has received
a scholarship and therefore no funding is requested for her. 
 Tea Pavlovic: PhD Candidate: Tea has taken over Dr. Dhan Chand`s work in
the laboratory. Her work is funding entirely by academic grants until the end of the year. I have requested additional funding for her to complete the work started by Dr. Chand in the new year. 

Choden Tenjin: PhD Candidate. Choden has reanalyzed all previous CRO associated behavioural studies and has led to a new synthesis of our
understanding of TCAP associated behaviour. She has been tasked with overseeing all behavioural studies. Because of her multinational background and ability to speak 7 languages, I have tasked her with overseeing the next set of behavioural studies
to support preclinical studies. 
 All other students are currently covered by academic grants. 

 APPENDIX “B-1” 

Project Budget 
  

					
	 Item
	  	Total, CA$	 
	 Total Direct Costs
	  	$	206,437	  
	 Indirect Costs at 15%
	  	$	30,966	  
		  	  
	  
	 
	 Total
	  	$	237,403	  
		  	  
	  
	 

 Payment schedule: 

University of Toronto will submit invoices to Sponsor according to the following schedule: 

 

							
	 Date:
	  	Payment:	  	CA$	 
	 24-Sep 2015
	  	1st installment	  	$	30,000	  
	 31-Oct 2015
	  	2nd installment	  	$	21,000	  
	 30-Nov 2015
	  	3rd installment	  	$	100,000	  
	 30-Jan 2016
	  	4th installment	  	$	86,403	  
		  		  	  
	  
	 
		  	Total	  	$	237,403	  
		  		  	  
	  
	 

 Payment method: 

Sponsor will pay via electronic wire transfer or cheque.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}]]